Todas las investigaciones
ReclutamientoFASE3INTERVENCIONISTA

Estudio de Extensión de Fase 3 de ADX-324 en Participantes con Angioedema Hereditario (HAE)

This study, called ADX-324-302, is for people who have already completed a previous trial for a condition called hereditary angioedema (HAE). HAE is a rare genetic disorder that causes episodes of severe swelling. This new study is an 'extension study,' meaning it follows on from the earlier trial. Its main purpose is to gather more information about how safe the medicine, ADX-324, is over a longer period and how well it helps control swelling attacks in people with Type 1 and Type 2 HAE. Researchers will also look at how the body handles the medicine and how it affects people's quality of life. This study is for adults aged 18 and over who have HAE.

De un vistazo

Estado
Reclutamiento
Fase
FASE3
Patrocinador
ADARx Farmacéuticos, Inc.
Objetivo de inscripción
90
Inicio
02 Apr 2026
Estimación de finalización
30 Jun 2030

¿De qué trata este estudio?

This study is a follow-up for people who have taken part in a previous clinical trial for hereditary angioedema (HAE). HAE is a conditions where people experience sudden, severe swelling in different parts of their body, which can be painful and sometimes life-threatening. The medicine being studied is called ADX-324.

The main goal of this particular study is to learn more about the long-term effects of ADX-324. While the previous study looked at its initial safety and effectiveness, this extension study will help doctors understand how well the medicine works over a longer time and if it continues to be safe for people with Type 1 and Type 2 HAE.

Researchers will also be checking how the body processes the medication and if it helps improve the daily lives of people living with HAE. This study is an important step in making sure new medicines are both safe and helpful for patients.

Puntos clave

  • This is an extension study for people with HAE who finished a previous trial.
  • It aims to learn more about the long-term safety and effectiveness of ADX-324 for HAE.
  • Participation involves continued medication and regular health check-ups.
  • The study includes adult participants (18 years and older) with Type 1 or Type 2 HAE.
  • Your well-being and access to acute HAE treatment are important throughout the study.

¿Quién puede ser elegible?

To join this study, you must have a confirmed diagnosis of hereditary angioedema (HAE), either Type 1 or Type 2. You would also need to have completed the previous study called ADX-324-301. It's also important that you have access to treatments for HAE attacks, such as certain medications that stop the swelling.

There are a few reasons why someone might not be able to join. For example, if you had a bad reaction to the study medicine (ADX-324) in the previous ADX-324-301 study, you wouldn't be able to participate in this extension. The study is open to adults aged 18 and older, both men and women.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. Do you have a confirmed diagnosis of hereditary angioedema (HAE) Type 1 or Type 2?
  2. Have you already completed the previous ADX-324-301 study?
  3. ¿Tienes 18 años o más?
  4. Do you have access to treatments for HAE attacks, if needed?
  5. Did you have a negative reaction to the study drug in the previous ADX-324-301 study? (If yes, you might not be eligible).
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you decide to take part, you would continue to receive doses of the study medicine, ADX-324. The study team would closely monitor your health and how you respond to the medicine. This will involve regular visits to the study clinic for assessments, which might include blood tests, physical examinations, and questionnaires about your health and how you are feeling. The exact number and frequency of visits, as well as the total duration you would be involved, would be explained in detail by the study team, as this is an extension study and builds upon previous participation.

Riesgos y beneficios potenciales

Taking part in any clinical study has potential benefits and risks. A potential benefit of this study is that you would continue to receive a study medicine that may help manage your HAE. It also contributes to vital research that could help others with HAE in the future. However, there are potential risks, including side effects from the medication, even if it was tolerated in the initial study. The potential side effects, and how they would be managed, will be fully explained to you. Remember, your participation is completely voluntary, and you are free to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (48)

  • ADARx Clinical Site
    Código postal verificado
    Litchfield Park, United States· Aún no reclutando
  • ADARx Clinical Site
    Código postal verificado
    Little Rock, Estados Unidos· Aún no reclutando
  • ADARx Clinical Site
    Código postal verificado
    San Diego, Estados Unidos· Aún no reclutando
  • ADARx Clinical Site
    Código postal verificado
    Walnut Creek, Estados Unidos· Aún no reclutando
  • ADARx Clinical Site
    Código postal verificado
    Orlando, Estados Unidos· Aún no reclutando
  • ADARx Clinical Site
    Código postal verificado
    Chevy Chase, United States· Aún no reclutando
  • ADARx Clinical Site
    Código postal verificado
    Wheaton, United States· Aún no reclutando
  • ADARx Clinical Site
    Código postal verificado
    Detroit, Estados Unidos· Aún no reclutando
  • ADARx Clinical Site
    Código postal verificado
    San Luis, Estados Unidos· Aún no reclutando
  • ADARx Clinical Site
    Código postal verificado
    Las Vegas, United States· Reclutamiento
  • ADARx Clinical Site
    Código postal verificado
    Nueva York, Estados Unidos· Reclutamiento
  • ADARx Clinical Site
    Código postal verificado
    Cincinnati, Estados Unidos· Aún no reclutando

Preguntas comunes

What is an 'extension study'?

An extension study is a follow-up study for people who have already taken part in an earlier trial. It helps researchers gather more information about a medicine over a longer period.

¿Qué es el angioedema hereditario (HAE)?

HAE is a rare genetic condition that causes sudden and repeated episodes of severe swelling in different parts of the body.

What is ADX-324?

ADX-324 is the specific medicine being studied in this trial for its potential to treat hereditary angioedema.

Will I receive treatment for my HAE attacks during the study?

Yes, if you join this study, you must still have access to your usual and approved treatments to manage any HAE attacks you might experience.

Who can participate in this study?

This study is for adults aged 18 and over who have a confirmed diagnosis of Type 1 or Type 2 HAE and have already completed the previous ADX-324-301 study.

Cómo obtener más información

Lupe Gallegos

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "Phase 3 Extension Study of ADX-324 in Participants With Here…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.